Use of Probiotics to Prevent Celiac Disease and IBD in Pediatrics
Authors:
- 20 December 2018
- book chapter
- Published by Springer Nature
- Vol. 1125, 69-81
Abstract
The incidence of chronic inflammatory diseases (CIDs) is increasing worldwide. Their dramatic rise associated with limited effective strategies to slow down these epidemics calls for a better understanding of their pathophysiology in order to decrease the burdens on childhood. Several cross-sectional studies have demonstrated the association between intestinal dysbiosis and active diseases. Although informative, these studies do not mechanistically link alterations of the microflora with disease pathogenesis and, therefore, with potential therapeutic targets. More prospective studies are needed to determine whether intestinal dysbiosis plays a causative role in the onset and development of CIDs. Furthermore, given the complexity of the microflora interaction with the host, it is necessary to design a systems-level model of interactions between the host and the development of disease by integrating microbiome, metagenomics, metatranscriptomics, and metabolomics with either clinical either environmental data. In this chapter we will discuss the current knowledge regarding the microbiome’s contribution to celiac disease and inflammatory bowel disease with a particular focus on how probiotics may be used as potential preventive therapy for CIDs.Keywords
This publication has 77 references indexed in Scilit:
- Human gut microbiome viewed across age and geographyNature, 2012
- Characterization of adherent-invasive Escherichia coli isolated from pediatric patients with inflammatory bowel diseaseInflammatory Bowel Diseases, 2012
- Genetics and pathogenesis of inflammatory bowel diseaseNature, 2011
- Identification of a novel immunomodulatory gliadin peptide that causes interleukin-8 release in a chemokine receptor CXCR3-dependent manner only in patients with coeliac diseaseImmunology, 2010
- Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled StudyAmerican Journal of Gastroenterology, 2010
- Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newbornsProceedings of the National Academy of Sciences, 2010
- Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2Proceedings of the National Academy of Sciences, 2009
- Gliadin Induces an Increase in Intestinal Permeability and Zonulin Release by Binding to the Chemokine Receptor CXCR3Gastroenterology, 2008
- Live probioticBifidobacterium lactisbacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell cultureClinical and Experimental Immunology, 2008
- Highly Efficient Gluten Degradation by Lactobacilli and Fungal Proteases during Food Processing: New Perspectives for Celiac DiseaseApplied and Environmental Microbiology, 2007